179042-26-3

Upstream product

• 1196-57-2 quinoxalin-2⁽¹⁾-one 
• 146651-75-4 tert–butyl (2–aminophenyl)carbamate 
• 38622-91-2 [(p-methylphenyl)sulfonylmethyl]isonitrile 
• 221025-36-1 N-(p-methoxybenzyl)-quinoxalin-2-one 
• 221025-37-2 5-(4-methoxybenzyl)imidazo[1,5-a]quinoxalin-4(5H)-one 

Downstream Products

• 221025-38-3 6-chloroimidazo[1,5-a]quinoxaline 

Relevant academic research and scientific papers

Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and?Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors

The transcription nuclear factor NF-κB plays a pivotal role in chronic and acute inflammatory diseases. Among the several and diverse strategies for inhibiting NF-κB, one of the most effective approach considered by the pharmaceutical industry seems to be

A Van Leusen deprotection-cyclization strategy as a fast entry into two imidazoquinoxaline families

A concise synthesis of two pharmacologically relevant classes of molecules possessing the imidazoquinoxaline core is reported. The protocol involves use of 1,2-phenylenediamines and glyoxylic acid derivatives, namely ethyl glyoxylate or benzylglyoxamide, along with tosylmethylisocyanides in a microwave-assisted Van Leusen three-component condensation. Subsequent unmasking (Boc removal) of an internal amino-nucleophile promotes deprotection and cyclization that take place either spontaneously in a one-pot fashion to give 8 or upon acidic treatment under microwave irradiation after isolation of the imidazole intermediate to give 11. Of note, a tricyclic framework is hence assembled by means of a rapid and straightforward method with a high bond-forming efficiency.

In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives

Imidazoquinoxaline and pyrazoloquinoxaline derivatives, analogues of imiquimod, were synthesized, and their in vitro cytotoxic and pharmacodynamic activities were evaluated. In vitro cytotoxicity studies were assessed against melanoma (A375, M4Be, RPMI-75

Reaction of quinoxalin-2-ones with TosMIC reagent: Synthesis of imidazo[1,5-a]quinoxalin-4-ones

Imidazo[1,5-a]quinoxalin-4-ones were prepared in four steps starting from 1,2-phenylenediamines using a new strategy for the construction of the ring system. A key step in this new method involves the reaction of quinoxalin-2-ones with TosMIC (tosylmethyl isocyanide).

Imidazoquinoxaline protein tyrosine kinase inhibitors

Novel imidazoquinoxalines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.

Imidazoquinoxaline protein tyrosine kinase inhibitors

Novel imidazoquinoxalines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.

Synthesis of imidazo[1,5-a]quinoxalin-4(5H)-one template via a novel intramolecular cyclization process

A novel, efficient, and regiospecific method for the construction of the imidazo[1,5-a]quinoxalin-4(5H)-one template is described. The key reaction involves an intramolecular cyclization process and provides the desired products in excellent yield.